DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin Comparator
Drug: vildagliptin

First Posted Date: 2004-12-22

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 570

Registration Number: NCT00099866

Locations: 🇩🇪
Novartis investigative Site, Investigative Sites, Germany

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Vildagliptin
Drug: Placebo
Drug: pioglitazone

First Posted Date: 2004-12-22

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 362

Registration Number: NCT00099853

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Phase 3

Completed

Conditions: Kidney Transplantation

First Posted Date: 2004-12-21

Last Posted Date: 2017-06-07

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00099801

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Drug: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Drug: MMF 2 g + full-dose Neoral (FDN) + corticosteroids

First Posted Date: 2004-12-20

Last Posted Date: 2017-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 696

Registration Number: NCT00099736

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Phase 2

Completed

Conditions: Kidney Transplantation

First Posted Date: 2004-12-20

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 255

Registration Number: NCT00099749

Locations: 🇺🇸
SIU School of Medicine, Springfield, Illinois, United States
🇺🇸
St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

Non-small Cell Lung Cancer Registry

Phase 4

Completed

Conditions: Non-Small-Cell Lung Cancer
Pleural Effusion, Malignant

First Posted Date: 2004-12-16

Last Posted Date: 2009-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT00099541

Locations: 🇺🇸
Hembree Cancer Center-St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States
🇺🇸
Gainesville Hematology Oncology Associates, Gainesville, Florida, United States
🇺🇸
Center for Cancer Care & Research, Lakeland, Florida, United States

and more 98 locations

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

Phase 3

Completed

Conditions: Dementia, Alzheimer Type
Alzheimer's Disease

First Posted Date: 2004-12-10

Last Posted Date: 2017-10-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1040

Registration Number: NCT00099242

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Carbidopa/levodopa/entacapone
Drug: Immediate release carbidopa/levodopa

First Posted Date: 2004-12-10

Last Posted Date: 2012-04-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 747

Registration Number: NCT00099268

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Keck School of Medicine, Division of Movement Disorders, Los Angeles, California, United States
🇺🇸
Reed Neurological Research Center, Los Angeles, California, United States

and more 29 locations

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Phase 3

Completed

Conditions: Vascular Dementia

First Posted Date: 2004-12-10

Last Posted Date: 2011-11-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 708

Registration Number: NCT00099216

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

First Posted Date: 2004-12-10

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 320

Registration Number: NCT00099229

Locations: 🇷🇺
Investigational Site, St. Petersburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy